None

Glenmark takes generic Malarone to UK after patent revoked

Glenmark Generics has launched a generic version of GlaxoSmithKline's combination antimalarial, Malarone (atovaquone plus proguanil) in the UK after a British High Court struck down the patent on the...

Human medicines European Public Assessment Report (EPAR): Crixivan, indinavir, Revision: 31, Authorised

India's Glenmark launches malaria treatment drug in UK

Feb 7 (Reuters) - Indian drugmaker Glenmark Pharmaceuticals Ltd said on Thursday its European unit had launched a generic version of GlaxoSmithKline's Malarone malaria treatment medicine, its first ge...

Chimerix Appoints Michael D. Rogers, Ph.D., as Chief Development Officer

RESEARCH TRIANGLE PARK, N.C., March 14, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today tha...

Arbor Pharmaceuticals Announces FDA Approval of First NDA

ATLANTA, May 13, 2013 /PRNewswire/ -- Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Nymalize™ (nimodipine...

NEOMED Institute Announces Inaugural Board of Directors

MONTREAL, Jan. 14, 2013 /PRNewswire/ - The NEOMED Institute disclosed on Monday, the composition of the inaugural Board of Directors. "I am extremely pleased today to identify the members of our fi...

Janssen Research & Development Submits Complete Response to the U.S. FDA on XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

RARITAN, N.J., Sept. 7, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that it has submitted the Complete Response to the U.S. Food and Drug Administration...

FDA Approves New 800mg PREZISTA® (darunavir) Tablet

TITUSVILLE, N.J., Nov. 9, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has approved a new 800mg tablet of PR...

Evidence-based Therapeutic Drug Monitoring for Indinavir.

The HIV protease inhibitor indinavir presents a wide inter-individual variability related to an intense hepatic metabolism. Published studies were analyzed to establish whether there is evidence that...

Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.

PURPOSE: To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-ad...

Development of Indinavir Submicron Lipid Emulsions Loaded with Lipoamino Acids-In Vivo Pharmacokinetics and Brain-Specific Delivery.

The aim of our present work was to develop indinavir O/W submicron lipid emulsions (SLEs) loaded with lipoamino acids for specific delivery to brain. Tetradecyl aspartic acid (A) and decyl glutamic ac...

Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo.

Many malaria-endemic areas are also associated with high rates of human immunodeficiency virus (HIV) infection. An understanding of the chemotherapeutic interactions that occur during malaria and HIV...

Chronic use of indinavir in albino rat pregnancy (Rattus norvegicus albinus, Rodentia, Mammalia): Biological assay.

Aim:  Assess possible adverse effects of the chronic use of indinavir during pregnancy in a rat model. Methods:  40 pregnant EOM-1 albino rats were randomly allocated into four groups of 10 animal...